NLS cantargia

Cantargia has reported new encouraging results from non-GLP toxicology and pharmacokinetic studies for its anti-inflammatory IL1RAP-binding antibody CAN10. Results show no toxicologically relevant changes using a new subcutaneous formulation, with high bioavailability and desirable pharmacological half-life, states the company. Further studies using intravenous administration show good safety by repeated dosing at 50 mg/kg. The GLP […]

Cantargia has reported treatment of the first triple negative breast cancer (TNBC) patient with nadunolimab and chemotherapy in the phase Ib/II clinical trial TRIFOUR. This trial, performed in collaboration with the Spanish Breast Cancer Group, GEICAM, will evaluate nadunolimab in combination with gemcitabine and carboplatin in up to 113 patients. Initially, the trial will focus […]

Cantargia has announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has issued a positive opinion for orphan designation of nadunolimab (CAN04) for treatment of pancreatic cancer. The European Commission is now expected to grant the orphan designation. This provides a range of incentives in the continued clinical development […]

Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy. The company has announced approval to start the phase I/II clinical study by the regulatory authority and ethics committee in France. “CESTAFOUR is a very important trial, designed to broaden the use of nadunolimab for patient groups with very high […]

The company expands the trial after successful completion of recruitment in the pembrolizumab combination arm. The last patient in the initial treatment arm of the phase Ib clinical study CIRIFOUR has started treatment. A total of 15 patients have so far been recruited to this study, which evaluates nadunolimab (CAN04) in combination with Keytruda (pembrolizumab), […]

Cantargia has announced the submission of the clinical trial application for TRIFOUR, a phase Ib/II trial investigating nadunolimab (CAN04) combined with gemcitabine and carboplatin for treatment of triple negative breast cancer (TNBC). After an initial safety lead in, the study will include a randomized phase II part. This trial will be performed in Spain in […]